Country’s leading manufacturer and exporter of medicine Beximco Pharmaceutical Ltd. (“Beximco Pharma” or the “Company”) has been awarded the prestigious CPhl Pharma Award in the category ‘Innovation in Response to COVID-19’ recently. The other finalists in this category include the world’s leading pharma companies namely Catalent USA, Aptar Pharma USA, Dr Reddy’s Laboratories India, Ridgeback Biotherapeutics/Merck USA, MedPharm UK and Crystec Pharma UK.
CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry judged by an esteemed panel of industry experts from around the world. Powered by Informa Pharma Intelligence, UK, the 17th annual CPhI Pharma Awards, at its first-ever virtual ceremony, honoured the outstanding achievements of those driving the global pharma industry forward through their innovations, technologies, and strategies.
Beximco Pharma became the first in the world to launch generic Remdesivir (under the brand name Bemsivir) and since then the company has been providing this drug-free of cost to Government designated COVID-19 hospitals in Bangladesh. Beximco Pharma has also supplied Remdesivir to a number of countries on humanitarian ground. Beximco Pharma is a leading exporter of pharmaceuticals in Bangladesh and it has a geographic footprint in more than 50 countries. Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory.
